1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. ALIVUS LIFE SCIENCES LTD.
Alivus Life Sciences Ltd.
NSE: ALIVUS | BSE: 543322

Alivus Life Sciences Live Share Price Today, Share Analysis and Chart

Strong Performer, Getting Expensive
aboutAlivus Life Sciences Ltd. (formerly Glenmark Life Sciences Ltd.) is a manufacturer and developer of high-value, non-commoditized Active Pharmaceutical Ingredients (APIs). The company focuses on chronic therapeutic areas, including cardiovascular dise... Read More
US FDA InspectionsANDA Approvals
Ask AI about Alivus Life Sciences
1415.3017.90(1.28%)

New 52W High today

1.5M
NSE+BSE Volume

High volume today

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Rapid Results
Q2FY27 Quarterly Result Announced for Alivus Life Sciences Ltd. See details
Loading...
- / 100
- / 100
66.1 / 100
Strong Performer, Getting ExpensiveThese stocks are strong in quality and technicals but have medium valuation. At somewhat expensive valuations, investors should be cautious before buyingView SimilarEmbed DVM
Analyst Price Target
-

34

S

6

W

2

O

4

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

16Positive7Negative

Pass in checklist69.6%

045
55
100

Check P/E Buy Sell Zone

Sell Zone

77.0 %    into P/E buy sell zone

% time spent below current P/E
020406080100
Strong upside potential
Gains already realized

Alivus Life Sciences Stock Price Analysis

Day Price Range

1.3% 1 Day return
1415.3 (LTP)
1,3801,499
LowHigh

Week Price Range

13.2% 1 Week return
1415.3 (LTP)
1,2221,499
LowHigh

Month Price Range

2.6% 1 Month return
1415.3 (LTP)
1,208.11,499
LowHigh

52 Week Price Range

56.5% 1 Year return
1415.3 (LTP)
8191,499
LowHigh
View full Price History/Seasonality

Alivus Life Sciences Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Miss

Alivus Life Sciences's Revenue was lower than average estimate 3 times in past 3 years

EPS forecast

CURRENT EPS
45.9
AVG. ESTIMATE
60.6
LOW ESTIMATE
60.6
HIGH ESTIMATE
60.6
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 32.0% in FY27

Consensus Recommendation

4 ANALYST Recommendations
STRONG BUY

The consensus recommendation from 4 analysts for Alivus Life Sciences is STRONG BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Alivus Life Sciences Technical Analysis

Alivus Life Sciences EMA & SMA

Bullish+8
8 bullish, 0 bearish
Bullish8
Bearish0
5 Day1373.2
10 Day1348
12 Day1344.5
20 Day1342.0
26 Day1342.6
50 Day1330.7
100 Day1271.8
200 Day1179.1

Alivus Life Sciences Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202645.7%
Week49.0%
Month52.5%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Alivus Life Sciences Resistance and Support

1431.43
Pivot
First Resistance1482.9
Second Resistance1550.4
Third Resistance1601.9
First Support1363.9
Second Support1312.4
Third Support1244.9
Day RSI62.8
Day MACD2
Day MFI81.2
Day MACD Signal Line-10.7

Alivus Life Sciences Beta

1 Month0.2
1 Year0.6
3 Month0.4
3 Year0.5

Alivus Life Sciences Price Change Analysis

↑2.6%
Over 1 Month
LowHigh
1208.11499
↑22.0%
Over 3 Months
LowHigh
1172.91499
↑36.3%
Over 6 Months
LowHigh
996.41499
↑56.5%
Over 1 Year
LowHigh
8191499
All Technicals →

Alivus Life Sciences Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Nirma LimitedPromoter91,896,28574.9 %
Government Pension Fund GlobalFii2,865,0002.3 %
Quant Mutual Fund - Quant Small Cap FundDii3,504,2962.9 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Alivus Life Sciences Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
ICICI PRUDENTIAL MUTUAL FUNDBulkPurchase04 Dec 2025870969,912BSE
BNP PARIBAS ARBITRAGEBlockSell25 Jan 2024799.55151,173BSE
SOCIETE GENERALEBlockPurchase25 Jan 2024799.55151,173BSE
POLAR CAPITAL FUNDS PLC-HEALTHCARE OPPORTUNITIES FUNDBulkPurchase09 Aug 2021732.55836,000NSE
NK SECURITIES RESEARCH PRIVATE LIMITEDBulkSell06 Aug 2021766.12951,097NSE
NK SECURITIES RESEARCH PRIVATE LIMITEDBulkPurchase06 Aug 2021765.77951,097NSE
All deals
All insider trades

Alivus Life Sciences Corporate Actions

Alivus Life Sciences Dividend history and yield

Alivus Life Sciences dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Alivus Life Sciences dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
101 Sep 2026
5FINAL01 Sep 2026Equity Share
201 Sep 2025
5FINAL01 Sep 2025Equity Share
317 Oct 2023
22.5INTERIM17 Oct 2023Equity Share
424 Mar 2023
21INTERIM24 Mar 2023Equity Share
515 Sep 2022
10.5FINAL-Equity Share

Alivus Life Sciences Board Meetings

Alivus Life Sciences past and upcoming board meetings.

#Ex-Date
PurposeNotes
129 Oct 2026
Quarterly Results-
230 Jul 2026
Quarterly Results-
314 May 2026
Audited Results & Final Dividend-
422 Jan 2026
Quarterly Results-
506 Nov 2025
Quarterly Results-
All Corporate Actions

Alivus Life Sciences Research Reports

Alivus Life Sciences research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
114 May 2026ICICI Direct
Target
12351044.6Buy18.23%35.49%pdf
222 Jan 2026ICICI Direct
Target
1190883.5Buy34.69%60.19%pdf
306 Nov 2025ICICI Direct
Target
1180915.05Buy28.95%54.67%pdf
417 Mar 2025BP Wealth13171065.75Buy23.57%32.8%pdf
525 Aug 2024ICICI Direct
Target
12951034.2Buy25.22%36.85%pdf
All Reports of Alivus

Alivus Life Sciences Corporate Filings

Alivus Life Sciences BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
30 Oct 2026
Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please find enclosed herewith intimation for Analyst/Investor Meet.
PDF
30 Oct 2026
Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
We hereby confirm that we have uploaded audio recording of the Q2 FY2027 Earnings Call held on October 30, 2026 on the website of the Company.
PDF
30 Oct 2026
Q2FY27 Quarterly Result Announced for Alivus Life Sciences Ltd.
Pharmaceuticals company Alivus Life Sciences announced Q2FY27 results Financial Highlights: Revenue from Operations: For Q2FY27 stood at Rs 6,819.87 million, demonstrating a growth of 6.49% QoQ from Rs 6,404.14 million and an increase of 15.99% YoY from Rs 5,879.80 million; for H1FY27 reached Rs 13,224.01 million, a 11.14% YoY increase compared to Rs 11,898.26 million. Total Income: For Q2FY27 stood at Rs 7,019.04 million, marking an expansion of 5.90% QoQ from Rs 6,628.15 million and a rise of 16.46% YoY from Rs 6,027.00 million; for H1FY27 reached Rs 13,647.19 million, growing by 12.46% YoY compared to Rs 12,135.31 million. Profit Before Tax (PBT): For Q2FY27 stood at Rs 2,619.74 million, accelerating by 23.44% QoQ from Rs 2,122.23 million and rising by 50.44% YoY from Rs 1,741.37 million; for H1FY27 reached Rs 4,741.97 million, registering a 40.66% YoY advancement compared to Rs 3,371.18 million. Profit After Tax (PAT): For Q2FY27 stood at Rs 1,967.45 million, scaling up by 22.91% QoQ from Rs 1,600.76 million and increasing by 51.31% YoY from Rs 1,300.26 million; for H1FY27 reached Rs 3,568.21 million, showing a 41.84% YoY increase over Rs 2,515.61 million. Earnings Per Share (EPS): For Q2FY27 stood at Rs 16.02, expanding by 22.85% QoQ from Rs 13.04 and advancing by 51.13% YoY from Rs 10.60; for H1FY27 reached Rs 29.06, reflecting a 41.69% YoY change compared to Rs 20.51. Yasir Rawjee, MD & CEO, Alivus Life Sciences, said: “Q2FY27 was another strong quarter for us, with revenue growing 16.0% YoY, supported by healthy demand across all key markets and robust contributions from recent launches. Non-GPL business momentum was maintained, while CDMO business saw a meaningful pick-up during the quarter. The improving business mix and greater operating efficiencies also translated into better underlying profitability. Looking ahead, our ongoing capacity expansion and healthy development pipeline give us confidence in sustaining this momentum and delivering consistent growth.” Tushar Mistry, CFO, Alivus Life Sciences, said: “We delivered a strong financial performance in Q2FY27, with healthy revenue growth, improved profitability and robust cash generation. Revenue grew 16.0% YoY, supported by a favourable product mix. Healthy operating performance translated into strong cash generation, with cash flow from operations of Rs. 270 crore during H1FY27. With cash and cash equivalents of Rs 1,012 crore as of September 30, 2026, we have ample financial flexibility to support our growth initiatives while maintaining a healthy, debt-free balance sheet. Going forward, we remain focused on sustaining profitable growth, maintaining financial discipline and creating long-term value.” Result PDF
PDF
30 Oct 2026
Alivus Life Sciences Results Earnings Call for Q2FY27
Conference Call with Alivus Life Sciences Management and Analysts on Q2FY27 Performance and Outlook. Listen to the full earnings transcript.
PDF
29 Oct 2026
Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Please find enclosed herewith intimation with respect to allotment of equity shares under "Employee Stock Option Scheme, 2021"
PDF
VIEW ALL

Alivus Life Sciences DocumentsAsk MarketMind AI

Alivus Life Sciences Earnings Call

Alivus Life Sciences earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
30 Oct 2026Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
30 Oct 2026Alivus Life Sciences Results Earnings Call for Q2FY27AudioVideo
07 Aug 2026Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
31 Jul 2026Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
31 Jul 2026Alivus Life Sciences Results Earnings Call for Q1FY27AudioVideo
view all

Alivus Life Sciences Annual Reports

Alivus Life Sciences financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Alivus Life Sciences Credit Ratings

Alivus Life Sciences credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
24 May 2022india ratingsIndia Ratings Affirms Glenmark Life Sciences at ‘IND AA-’/StableLink

Alivus Life Sciences Investor Presentations

Alivus Life Sciences investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
29 Oct 2026Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
30 Jul 2026Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
14 May 2026Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
22 Jan 2026Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
06 Nov 2025Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Alivus Life Sciences - Company Profile

Alivus Life Sciences Management Structure

Alivus Life Sciences management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Yasir Yusufali RawjeeExecutive Director,Managing Director,Chief Executive Officer1637.8Mar 26
Vinod NaikExecutive Director,Whole Time Director,Head(Technical Operations)369Mar 26
Mr. Tushar MistryGroup Vice President,Chief Financial Officer-Mar 26
Mr. Sumantra MitraSenior Vice President,Head(Human Resources)-Mar 26
Dr. Palle V R AcharyuluExecutive Vice President,Head(Research & Development)-Mar 26
Mr. Navin Kumar AgrawalSenior Vice President,Head(Corporate Quality)-Mar 26
Mr. Mathew GeorgeSenior Vice President,Head(Regulatory Affairs)-Mar 26
Mr. Mihir DoshiVice President(Sales,Marketing,Product Management)-Mar 26
Mr. Gautam AroraVice President(Sales,Marketing,Product Management)-Mar 26
Mr. Amol KirtaniVice President(Sales,Marketing,Product Management)-Mar 26
Ms. Anshu RazdanSenior General Manager(Sales,Marketing,Product Management)-Mar 26
Mr. Sachin UttekarVice President(Procurement)-Mar 26
Rudalf CorrieaCompany Secretary,Compliance Officer-Mar 26

Alivus Life Sciences Board of Directors

Alivus Life Sciences Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Yasir Yusufali RawjeeManaging Director & CEO1637.8Mar 26
Vinod NaikED / WTD / Head - Technical & Operations369Mar 26
Kaushikbhai N. PatelIndependent Non Exe. Director15Mar 26
Savan GodialwalaIndependent Non Exe. Director14Mar 26
Manju AgarwalIndependent Non Exe. Director13Mar 26
Taruvai Laxminarayanan EaswarIndependent Non Exe. Director11Mar 26
Hiren K. PatelChairman & Non Executive Dir.-Mar 26
Rudalf CorrieaCompany Sec. & Compli. Officer-Mar 26
Website: www.glenmarklifesciences.com

About the company - Business Profile

Alivus Life Sciences Ltd. (formerly Glenmark Life Sciences Ltd.) is a manufacturer and developer of high-value, non-commoditized Active Pharmaceutical Ingredients (APIs). The company focuses on chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system (CNS), pain management, and diabetes. As of early 2024, the company transitioned to new ownership under Nirma Limited, marking a shift from its captive beginnings under Glenmark Pharmaceuticals to an independent global entity. Alivus serves over 700 customers across more than 75 countries, maintaining a significant presence in regulated markets such as North America, Europe, and Japan.

Key Points

  • Key Facts: Founded as a separate entity in 2011 (carved out from Glenmark Pharmaceuticals in 2019), Alivus is headquartered in Mumbai, India. Following a majority stake acquisition by Nirma Limited in 2024, it was rebranded as Alivus Life Sciences Ltd. with effect from December 17, 2024. The company is listed on the BSE and NSE.
  • Operations and Resources: The company operates four manufacturing facilities in India:
    • Ankleshwar, Gujarat: 950.2 KL annual installed capacity.
    • Dahej, Gujarat: 399.9 KL annual installed capacity.
    • Mohol, Maharashtra: 49.1 KL annual installed capacity.
    • Kurkumbh, Maharashtra: 24.6 KL annual installed capacity.

      Total annual installed capacity stands at approximately 1,424 KL as of September 2025.

  • Strategic Assets: A new greenfield facility is under development in Solapur with a planned capacity of 1,000 MT (Phase 1 construction of 200 KL is underway). The company has also acquired 10,000 square meters of land in Taloja, Navi Mumbai, to establish a research center focused on complex chemistry and oncology.
  • Business Model and Expertise: Alivus operates a dual business model:
    • Generic API: Focusing on high-volume, chronic therapeutic areas with a portfolio of 165 APIs.
    • CDMO (Contract Development and Manufacturing): Providing specialized manufacturing services to global pharmaceutical innovators.
  • Revenue Breakdown (FY25):
    • Income from Operations: ₹23,868.84 million (Growth of 4.5% YoY from ₹22,832.14 million in FY24).
    • Net Profit After Tax: ₹4,856.27 million (FY25) compared to ₹4,708.88 million (FY24).
    • Segmental Contribution: Generic API continues to be the dominant segment, though CDMO showed a recovery in the latter half of 2025, growing 85.3% YoY in Q3FY26.
    • Client Concentration: Sales to the former parent, Glenmark Pharmaceuticals (GPL), represented approximately 24.4% of revenue in Q2FY26, while Non-GPL revenue contributed 75.6%.
  • Innovation and Portfolio: As of December 31, 2025, the company has filed 595 DMFs and CEPs across major global markets. The R&D pipeline includes 27 products in the High Potency (HP) API segment and active development in iron complex platforms.
  • Financial Health: The company maintains a strong balance sheet with cash and cash equivalents of ₹7,330 million as of December 31, 2025. The EBITDA margin remained steady at approximately 30% in FY25.
  • Strategic Initiatives: Future growth levers include expanding the CDMO business, scaling the Oncology and Iron compound portfolios, and geographical expansion into newly regulated emerging markets.

References

  1. Annual Report May 2025
  2. Investor Presentation Nov 2025
  3. Investor Presentation Jan 2026
  4. Quarterly Results Nov 2025

Alivus Life Sciences FAQ

Alivus Life Sciences today is trading in the green, up by 1.28% at ₹1,415.3.
Alivus Life Sciences is currently trading up 1.28% on an intraday basis. In the past week the stock rose 13.17%. Stock has been up 22.01% in the past quarter and rose 56.48% in the past year. You can view this in the share price history/seasonality section.
Alivus Life Sciences is listed on NSE with the ticker ALIVUS and on BSE as 543322. It's currently trading on NSE at a share price of ₹1,415.3 and on BSE with a share price of ₹1,407.8.
The market cap of Alivus Life Sciences is ₹17,403.56 Cr. as of Oct 30, 2026.
Alivus Life Sciences announced a FINAL dividend of 250% which equals ₹5 in Sep 01, 2026.The last three ex-dates for Alivus Life Sciences were Sep 01, 2025, Oct 17, 2023 and Mar 24, 2023. To view the full dividend history of Alivus Life Sciences click here.
Alivus Life Sciences has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.
Alivus Life Sciences reported ₹701.9 Cr. in revenue, ₹196.74 Cr. in net profit, and ₹285.1 Cr. in EBITD as of Oct 29, 2026 for Q2 FY26-27.
According to the predictions of 4 analysts, the share price prediction for Alivus Life Sciences is ₹1,432.25 with an upside of 1%.
The PE ratio of Alivus Life Sciences is 25.99 as of Oct 30, 2026.
The PB ratio of Alivus Life Sciences is 4.98 as of Oct 30, 2026.
You can view the latest analyst reports on the Alivus Life Sciences reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×